Strategic Acquisition Hologic Diagenode operates under the umbrella of Hologic, following a 2021 acquisitions milestone that expanded its reach. This indicates potential cross-sell opportunities with Hologic’s broader diagnostic portfolio and access to merged sales channels.

Epigenomics Focus Specializes in epigenomics profiling and sample preparation for next generation sequencing, proteomics, and epigenetics research, signaling opportunities to upsell integrated sample prep, sequencing workflows, and related reagents or services to labs expanding epigenetic capabilities.

Small Player, Niche Small- to mid-sized team (51-200 employees) with revenue in the low tens of millions, suggesting high-touch, relationship-driven sales motions and opportunities to partner with larger distributors or integrators while offering tailored solutions.

Recent Product Launches Recent introductions such as the D-Plex Small RNA DNBSEQ Kit indicate ongoing product development and potential for expansion into small RNA sequencing workflows, enabling cross-sell of complementary kits, services, and platform-optimized protocols.

Multi-Platform Collaboration History of collaborations and platform partnerships (e.g., with Panther Fusion assays and mRNA-seq services via Alithea Genomics) suggests readiness to engage in co-development, licensing, or reseller arrangements with other diagnostics and sequencing platforms to reach broader customer bases.